The DOI matches its Crossref record, with a small difference in title or year; 15 of the 15 references it cites were found in a registry or an index.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain. METHODS: We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death, as assessed in a time-to-event analysis. RESULTS: Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the dapagliflozin group and in 610 of 3132 patients (19.5%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.92; P<0.001). Worsening heart failure occurred in 368 patients (11.8%) in the dapagliflozin group and in 455 patients (14.5%) in the placebo group (hazard ratio, 0.79; 95% CI, 0.69 to 0.91); cardiovascular death occurred in 231 patients (7.4%) and 261 patients (8.3%), respectively (hazard ratio, 0.88; 95% CI, 0.74 to 1.05). Total events and symptom burden were lower in the dapagliflozin group than in the placebo group. Results were similar among patients with a left ventricular ejection fraction of 60% or more and those with a left ventricular ejection fraction of less than 60%, and results were similar in prespecified subgroups, including patients with or without diabetes. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risk of DKA is increased in persons using SGLT2is, especially in those being treated with insulin (especially if there has been a recent reduction in their insulin dose) and/or those with acute illnesses and prolonged fasting.1049,1050”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1049]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) and DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), SGLT2 inhibition reduced the risk of cardiovascular death and worsening HF events by 18% to 21%4,5 and improved KCCQ-CSS by 1.5 to 2.3 points”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (302).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (290).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [290]
In the citing paper
“Sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary composite outcome of CV death and total HF hospitalization by 22% in those with an LVEF below or equal to the median of 57%.534”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“DELIVER recruited 6263 patients with heart failure with mildly reduced or preserved (>40%) ejection fraction including 3109 patients without diabetes.”
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
In the citing paper
“Since 2021, two placebo-controlled SGLT2 inhibitor trials (EMPA-KIDNEY and DELIVER) have studied a large number of people without diabetes.”
In the citing paper
“Approximately 44% of patients randomized to either dapaglifl ozin or placebo had type 2 diabetes, and results were consistent regardless of the presence of type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
In the citing paper
“The primary outcome of a composite of worsening heart failure, de fi ned as hospitalization or urgent visit for heart failure, or cardiovascular death was reduced by 18% in patients treated with dapagli fl ozin compared with placebo (HR 0.82 [95% CI 0.73 -0.92]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationCategorical Data Analysis Using the SAS System
Ziegel, E. R., Stokes, M., Davis, C., & Koch, G. (1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 2,034
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationSolomon, S. D., Claggett, B. L., Lewis, E. F., Desai, A. S., Anand, I. S., Sweitzer, N. K., O’Meara, E., Shah, S. J., McKinlay, S. M., Fleg, J. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv464 · Cited by 538
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,002
Leite, M., Sampaio, F., Saraiva, F. A., Diaz, S. O., Barros, A. S., & Fontes‐Carvalho, R. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14284 · Cited by 14
NHC/ SHA 2023 Focused update of the 2019 guidelines for the management of heart failure
Habeeb, W. A., Tash, A. A., Elasfar, A., Almasood, A. S., Bakhsh, A., Elshaer, F., Ayoubi, F. A., Alghalaini, K., Alqaseer, M., Alhussein, M., et al. (2023) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1334 · Cited by 16
Acute Glycemic Variability and Early Outcomes After Cardiac Surgery: A Meta-Analysis
Chang, S., Xu, M., Wang, Y., & Zhang, Y. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2106-5539 · Cited by 15
Marzo, V. D., Savarese, G., Porto, I., Metra, M., & Ameri, P. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001504 · Cited by 14
Daniels, L. J., Macindoe, C., Koutsifeli, P., Annandale, M., James, S. L., Watson, L. E., Coffey, S., Raaijmakers, A. J. A., Weeks, K. L., Bell, J. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39499-3 · Cited by 15
Sohn, M., Frías, J. P., & Lim, S. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15251 · Cited by 16
Muñoz, D. R., Crespo‐Leiro, M. G., Lozano, I. F., Gómez, J. L. Z., Peinado, R., Manzano, L., Bagudá, J. D. J., Castillo, A. M. D., Arribas, F., & Bodes, R. S. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14488 · Cited by 15
Kommu, S. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001511 · Cited by 17
Suzuki, Y., Kaneko, H., Okada, A., Ohno, R., Yokota, I., Fujiu, K., Jo, T., Takeda, N., Morita, H., Node, K., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02246-6 · Cited by 15
Kongmalai, T., Hadnorntun, P., Leelahavarong, P., Kongmalai, P., Srinonprasert, V., Chirakarnjanakorn, S., Chaikledkaew, U., McKay, G. J., Attia, J., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1216160 · Cited by 18
Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF
Capone, F., Nambiar, N., & Schiattarella, G. G. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001117 · Cited by 15
Horiuchi, Y., Asami, M., Yahagi, K., Oshima, A., Gonda, Y., Yoshiura, D., Komiyama, K., Yuzawa, H., Tanaka, J., Aoki, J., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061670 · Cited by 17
Sarzani, R., Landolfo, M., Pentima, C. D., Ortensi, B., Falcioni, P., Sabbatini, L., Massacesi, A., Rampino, I., Spannella, F., & Giulietti, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1365183 · Cited by 18
Scarà, A., Palamà, Z., Robles, A. G., Dei, L., Borrelli, A., Zanin, F., Pignalosa, L., Romano, S., & Sciarra, L. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040122 · Cited by 16
Doiron, J. E., Xia, H., Yu, X., Nevins, A., LaPenna, K. B., Sharp, T. E., Goodchild, T. T., Allerton, T. D., Elgazzaz, M., Lazartigues, E. D., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16493 · Cited by 15
Self-citationEffect of extracellular matrix stiffness on efficacy of Dapagliflozin for diabetic cardiomyopathy
Zhu, T., Ye, Z., Song, J., Zhang, J., Zhao, Y., Xu, F., Wang, J., Huang, X. S., Gao, B., & Li, F. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02369-x · Cited by 16
Butt, J. H., McMurray, J. J. V., Claggett, B. L., Jhund, P. S., Neuen, B. L., McCausland, F. R., Desai, A. S., Lam, C. S. P., Pitt, B., Pfeffer, M. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.071110 · Cited by 17
Self-citationSchwegel, N., Toferer, C., Zach, D. K., Santner, V., Höller, V., Lugitsch, J., Wallner, M., Gollmer, J., Aziz, F., von Lewinski, D., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195966 · Cited by 15
Healy, L., Giblin, G. T., Gray, A., Starr, N., Murphy, L., O'Sullivan, D., Kavanagh, E. C., Howley, C., Tracey, C., Morrin, E., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15112 · Cited by 15
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 15
Implementation of Guideline-Recommended Medical Therapy for Patients with Heart Failure in Europe
Volterrani, M., Seferovic, P., Savarese, G., Spoletini, I., Imbalzano, E., Bayés‐Genís, A., Jankowska, E. A., Senni, M., Metra, M., Chioncel, O., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15105 · Cited by 15
Towards a phenotype profiling of the patients with heart failure and preserved ejection fraction
Bonfioli, G. B., Pagnesi, M., Calò, L., & Metra, M. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae095 · Cited by 15
Can sodium-glucose cotransporter 2 inhibitors ‘spin the thread of life’?
Maltese, G., Koufakis, T., Kotsa, K., & Karalliedde, J. J. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.10.002 · Cited by 15
Lin, Y., Cai, Z., Yuan, J., Liu, H., Pang, X., Chen, Q., Tang, X., Geng, Q., & Dong, S. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01679-2 · Cited by 16
Yuyun, M. F., Kinlay, S., Singh, J. P., & Joseph, J. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14248 · Cited by 15
Basile, C., Paolillo, S., Gargiulo, P., Marzano, F., Asile, G., Parlati, A. L. M., Chirico, A., Nardi, E., Buonocore, D., Colella, A., et al. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001411 · Cited by 17
Saw, E. L., Werner, L. D., Cooper, H. L., Pimental, D. R., Zamani, P. L., Chirinos, J. A., Valero‐Muñoz, M., & Sam, F. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012350 · Cited by 15
Obesity and heart failure: exploring the cardiometabolic axis
Rayner, J. J., Abdesselam, I., Pan, J., Lewis, A., & Rider, O. J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf090 · Cited by 15
Hong, D., Song, S.-H., Shin, H., Bak, M., Kim, J., Kim, D., Kim, J. Y., Yang, J. H., Park, S.-J., Choi, J.-O., et al. (2025) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztaf080 · Cited by 14
Parker, A. M., Lees, J. G., Murray, A. J., Velagic, A., Lim, S. Y., Blasio, M. J. D., & Ritchie, R. H. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101345 · Cited by 16
Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes
Alghamdi, M., Dihoum, A., Hakami, K., Bhattacharjee, A., Brown, A. J. M., Singh, J. S., Al-Talabany, S., Lang, C. C., Mordi, I. R., & Khan, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70164 · Cited by 14
Minisy, M. M., & Abdelaziz, A. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05127-3 · Cited by 14
Monzo, L., Savarese, G., Müllens, W., Abdin, A., Bozkurt, B., Chioncel, O. D., Hadidi, S. E., Gorter, T. M., Inciardi, R. M., Petrie, M. C., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70082 · Cited by 16
Ma, S., Chen, L., Yan, J., Shen, M., Zhang, R., Li, M., He, M., Chen, K., Zhu, Y., Lin, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113765 · Cited by 14
Theofilis, P., Vordoni, A., & Kalaitzidis, R. (2022) · Life · doi:10.3390/life12101663 · Cited by 14
Novel Strategies to Improve Prescription of Guideline-Directed Medical Therapy in Heart Failure
Brooksbank, J. A., Faulkenberg, K. D., Tang, W. H. W., & Martyn, T. (2023) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-023-00979-4 · Cited by 14
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
Scheen, A. J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2210673 · Cited by 15
Kasprzak, J. D., Gorczyca-Głowacka, I., Sobczak, M., Barylski, M., Dróżdż, J., Filipiak, K. J., Kapłon‐Cieślicka, A., Lelonek, M., Mamcarz, A., Ochijewicz, D., et al. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0110 · Cited by 16
Peikert, A., Chandra, A., Kosiborod, M., Claggett, B. L., Desai, A. S., Jhund, P. S., Lam, C. S. P., Inzucchi, S. E., Martínez, F. A., de Boer, R. A., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1342 · Cited by 14
Self-citationCardiorenal interactions in heart failure: insights from recent therapeutic advances
Damman, K., & Testani, J. M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad096 · Cited by 17
Łuniewski, M., Matyjaszek‐Matuszek, B., & Lenart-Lipińska, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134431 · Cited by 15
Voors, A. A. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.08.017 · Cited by 14
Tilinca, M. C. (2023) · FARMACIA · doi:10.31925/farmacia.2023.4.4 · Cited by 14
Vernooij, R. W. M., van Ommen, A. M. L. N., Valstar, G., Cramer, M. J., Teske, A. J., Menken, R., Hofstra, L., Rutten, F. H., Bots, M. L., den Ruijter, H. M., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14511 · Cited by 14
de Germay, S., Pambrun, É., Pariente, A., Grenet, G., Bezin, J., & Faillie, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15472 · Cited by 14
Frailty in clinical drug trials: Frailty assessments, subgroup analyses and outcomes
Nguyen, T. N., Ahmad, F., & Lindley, R. I. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16034 · Cited by 14
Dapagliflozin and Timing of Prior Heart Failure Hospitalization
Butt, J. H., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., Martínez, F. A., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.01.018 · Cited by 14
Self-citationSodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives
Mondal, S., Pramanik, S., Khare, V. R., Fernandez, C. J., & Pappachan, J. M. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i5.240 · Cited by 14
Brown, S., Biswas, D., Wu, J., Ryan, M. J., Bernstein, B. S., Fairhurst, N., Kaye, G., Baral, R., Cannata, A. N., Searle, T., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101064 · Cited by 14
Heart failure with preserved ejection fraction: The role of inflammation
Liu, H., Magaye, R., Kaye, D. M., & Wang, B. H. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176858 · Cited by 17
Clinical Update in Heart Failure with Preserved Ejection Fraction
Krittanawong, C., Britt, W., Rizwan, A. M., Siddiqui, R., Khawaja, M., Khan, R., Joolharzadeh, P., Newman, N. A., Rivera, M. R. R., & Tang, W. H. W. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00679-5 · Cited by 17
Amioka, M., Kinoshita, H., Fuji, Y., Nitta, K., Yamane, K., Shokawa, T., & Nakano, Y. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15088 · Cited by 17
Natural language processing to adjudicate heart failure hospitalizations in global clinical trials
Marti-Castellote, P. M., Reeder, C., Claggett, B., Singh, P., Lau, E. S., Khurshid, S., Batra, P., Lubitz, S. A., Maddah, M., Vardeny, O., et al. (2025) · Circulation: Heart Failure · doi:10.1161/circheartfailure.124.012514 · Cited by 14
Self-citationLin, M., Zhang, S., Zhang, L., Yang, C., Yang, L., Peng, Y., Tan, X., Wen, Q., Fan, X., & Ou, X. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02766-7 · Cited by 14
Yang, M., Kondo, T., Talebi, A., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S. P., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.10.020 · Cited by 14
Self-citationSGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
Huang, B., Yen, C., Wu, C., Tsai, C., Chen, J., Hsiao, C.-C., Chen, Y., Hsieh, I.-C., & Yang, H. (2025) · Scientific Reports · doi:10.1038/s41598-024-81973-z · Cited by 14
Landucci, L., Faxén, U. L., Benson, L., Rosano, G. M. C., Dahlström, U., Lund, L. H., & Savarese, G. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037502 · Cited by 14
Clinical pharmacology of SGLT-2 inhibitors in heart failure
Velliou, M., Polyzogopoulou, E., Ventoulis, I., & Parissis, J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2173574 · Cited by 16
McEwan, P. C., FOOS, V., Martin, B., Chen, J., & Evans, M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15040 · Cited by 13
Sim, D., Lin, W., Sindone, A. P., Yingchoncharoen, T., Prameswari, H. S., Ghazi, A. M., Pin, L. C., Teo, L. L. Y., Aw, T. C., Agbayani, M. F., et al. (2023) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2022.42 · Cited by 14
Beles, M., Masuy, I., Verstreken, S., Bartúnek, J., Dierckx, R., Heggermont, W., Oeste, C. L., Boeck, M. D., Fovel, I., Maris, M., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14381 · Cited by 14
Ohte, N., Kikuchi, S., Iwahashi, N., Kinugasa, Y., Dohi, K., Takase, H., Masai, K., Inoue, K., Okumura, T., Hachiya, K., et al. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae033 · Cited by 14
SGLT2 inhibitors and diuretics in heart failure: clicking reset on the renal volume setpoint?
Borlaug, B. A., & Testani, J. M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad345 · Cited by 14
Intracellular pH Regulation in Ventricular Myocytes: Implications for Cardiac Health and Disease
Orlowski, A., Mattia, R. A. D., & Aiello, E. A. (2025) · Circulation Research · doi:10.1161/circresaha.125.325386 · Cited by 13
Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure in US Ambulatory Cardiovascular Care
Rafei, A. E., GOSCH, K. L., Manning, E. S., Ghajar, A., Raghavan, S., Maddox, T. M., Peterson, P. N., Fleming, L., Arnold, S. V., Chan, P. S.-F., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.2145 · Cited by 13
Zheng, W., Qi, Q., Li, J., He, C., & Fan, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01917-z · Cited by 17
Aging and metabolism in HFpEF: Pathophysiology and therapeutic implications
Ye, M., Feng, S., Xu, Z., He, W., Liu, C., & Zhu, W. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156460 · Cited by 15
Heart failure in the elderly: epidemiology, mechanisms, and management
de Boer, R. A., Abdellatif, M., Bauersachs, J. K., & Roger, V. L. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag110 · Cited by 20
Mendieta, G., Ridker, P. M., Borlaug, B. A., Ducharme, A., Lam, C. S. P., Voors, A. A., Auerbach, P., Čikeš, M., Fudim, M., Hvelplund, A., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag153 · Cited by 15
Self-citationKittleson, M. D., Panjrath, G. S., Bates, K., Breathett, K. K., Dixon, D. L., Januzzi, J. L., & Mohammed, S. F. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.018 · Cited by 16
Raval, M., Siddiq, S., Sharma, K. H., Sanghvi, L., Jain, A., Patel, S., Trivedi, J., Chandani, K. U., Patel, D., & Desai, R. (2023) · F1000Research · doi:10.12688/f1000research.130285.1 · Cited by 13
Nakagaito, M., Imamura, T., Ushijima, R., Nakamura, M., & Kinugawa, K. (2023) · Biomedicines · doi:10.3390/biomedicines11030876 · Cited by 14
Sagris, D., Ntaios, G., & Milionis, H. J. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329149 · Cited by 13
Fazio, S., Mercurio, V., Affuso, F., & Bellavite, P. (2023) · Biomedicines · doi:10.3390/biomedicines11112928 · Cited by 13
Cases, A., Cigarrán, S., Górriz, J. L., & Núñez, J. E. (2023) · Nefrología · doi:10.1016/j.nefro.2023.11.001 · Cited by 14
Ketones provide an extra source of fuel for the failing heart without impairing glucose oxidation
Pherwani, S., Connolly, D., Sun, Q., Karwi, Q. G., Carr, M., Ho, K. L., Wagg, C. S., Zhang, L., Levasseur, J. L., Silver, H. L., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155818 · Cited by 16
Effect of SGLT2 inhibitors on anemia and their possible clinical implications
Cases, A., Cigarrán, S., Górriz, J. L., & Núñez, J. E. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.03.011 · Cited by 15
Optimising Transitional Care Following a Heart Failure Hospitalisation in Australia
Sindone, A. P., Driscoll, A. L., Audehm, R. G., Sverdlov, A. L., McVeigh, J., Chan, W. P. A., Hickey, A., Hopper, I., Chang, T., Maiorana, A., et al. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.11.029 · Cited by 16
Tuttle, M. L., Fang, J. C., Sarnak, M. J., & McCallum, W. I. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151516 · Cited by 16
Self-citationUse of Sodium–Glucose Cotransporter 2 Inhibitors in Hospitalized Patients
Ünlü, O., Bhatt, A. S., & Blood, A. J. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101024 · Cited by 13
New Perspectives in Management of Cardiovascular Risk Among People With Diabetes
Gami, A., Blumenthal, R. S., McGuire, D. K., Sarkar, S., & Kohli, P. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034053 · Cited by 13
Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors
Komaniecka, N., Maroszek, S., Droździk, M., Oswald, S., & Droździk, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136926 · Cited by 14
Newland, D. M., Law, Y. M., Albers, E. L., Ali, R., Friedland‐Little, J. M., Hartje‐Dunn, C., Kemna, M. S., Knorr, L. R., Nemeth, T. L., Spencer, K. L., et al. (2024) · Pediatric Cardiology · doi:10.1007/s00246-024-03604-8 · Cited by 13
D’Italia, G., Schroen, B. L. M., & Cosemans, J. M. E. M. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15090 · Cited by 13
Hill, L., Girerd, N., Castiello, T., Jaarsma, T., Metra, M., Rosano, G. M. C., Savage, P., Schuuring, M. J., Simpson, M., Uchmanowicz, I., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3519 · Cited by 13
Jung, M., Cho, J. S., Lee, S., Youn, J., Choi, Y., Chung, W., Lee, J., Kang, D., Kwon, W., Kim, T., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae345 · Cited by 14
Bahlmann-Kroll, E., Häckl, S., Kramer, S., Wulfmeyer, V. C., Glandorf, J., Kaufeld, J. K., Koch, A., Hartung, D., Schmidt, B. M. W., Schmidt-Ott, K. M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088317 · Cited by 13
Maremmani, M., Ebrahimi, R., Centola, M., Achilli, F., Capone, V., Bossone, E., Templin, C., & Vece, D. D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02592-0 · Cited by 13
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 13
Cannarella, R., Rubulotta, M., Cannarella, V., Vignera, S. L., & Calogero, A. E. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.010 · Cited by 14
Baris, R. O., & Tabit, C. E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165894 · Cited by 17
Tornyos, D., Meuer, M., Lukács, R., Abdallaoui, O. E. A. E., Kupó, P., Faludi, R., & Komócsi, A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1041200 · Cited by 15
Lorenzi, A. B. D., Kaplinsky, E., Zambrano, M. R., Chaume, L. T., & Rosas, J. M. (2023) · Drugs in Context · doi:10.7573/dic.2022-7-1 · Cited by 16
Lee, K., Noh, J. H., Park, S., Choi, K. M., Kang, S., Won, K. C., Cho, H., Moon, M. K., & Korean Society of Heart Failure (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0420 · Cited by 13
The role of glucose in cardiac physiology and pathophysiology
Mylonas, N., Drosatos, K., & Mia, S. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000943 · Cited by 14
Sato, T., Kouzu, H., Yano, T., Sakuma, I., Furuhashi, M., & Tohse, N. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1159953 · Cited by 13
Myofilament dysfunction in diastolic heart failure
Aboonabi, A., & McCauley, M. D. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10352-z · Cited by 14
Banerjee, M., Pal, R., Maisnam, I., & Mukhopadhyay, S. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102943 · Cited by 14
Bozkurt, B. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.07.001 · Cited by 13
Wei, H., Ye, L., Li, M., Huang, S., & Mo, Z. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf075 · Cited by 12
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., Fang, J. C., Alcocer-Gamba, M. A., Al Habeeb, W., Han, Y., Cabrera Honorio, J. W., Janssens, S. P., Katova, T., Kitakaze, M., Merkely, B., O’Meara, E., Saraiva, J. F. K., Tereshchenko, S. N., Thierer, J., Vaduganathan, M., Vardeny, O., Verma, S., Pham, V. N., Wilderäng, U., Zaozerska, N., Bachus, E., Lindholm, D., Petersson, M., & Langkilde, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., B.C., A.S.D., M.V.); the British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom (J.J.V.M., P.S.J.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (R.A.B., C.S.P.L.), and Haga Teaching Hospital, the Hague (C.J.W.B.) — both in the Netherlands; the University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (A.F.H.); Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (M.N.K.); National Heart Center Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); National University of Cordoba, Cordoba (F.M.), and Jefe de Unidad de Insuficiencia Cardíaca, Centro de Educación Médica e Investigaciones Clínicas Norbert...
- Northwestern University (US)
- Semmelweis University (HU)
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Claggett, Brian
- de Boer, Rudolf A.
- DeMets, David
- Hernandez, Adrian F.
- Inzucchi, Silvio E.
- Kosiborod, Mikhail N.
- Lam, Carolyn S.P.
- Shah, Sanjiv J.
- Desai, Akshay S.
- Jhund, Pardeep S.
- Chiang, Chern-En
- Dobreanu, Dan
- Fang, James C.
- Alcocer-Gamba, Marco Antonio
- Han, Yaling
- Janssens, Stefan P.
- Kitakaze, Masafumi
- Merkely, Béla
- O’Meara, Eileen
- Tereshchenko, Sergey N.
- Thierer, Jorge
- Vaduganathan, Muthiah
- Vardeny, Orly
- Verma, Subodh
- Pham, Vinh Nguyen
- Wilderäng, Ulrica
- Bachus, Erasmus
- Lindholm, Daniel
- Petersson, Magnus
- Langkilde, Anna Maria
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-09-22
- Volume
- 387
- Issue
- 12
- Pages
- 1089-1098
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4293354639
- Cited by
- 2,884
- References
- 15
- Citations by year
- 2026: 635 · 2025: 716 · 2024: 714 · 2023: 673 · 2022: 139
- FWCI
- 390.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Lirias (KU Leuven) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- dapagliflozin, SGLT2 inhibitors, heart failure, preserved ejection fraction, mildly reduced ejection fraction, heart failure hospitalization, cardiovascular mortality, left ventricular ejection fraction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Heart Failure, Humans, Stroke Volume, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
